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Cardiac resynchronization therapy in patients with a narrow QRS
Abstract
Although cardiac resynchronization therapy (CRT) is indicated in patients with moderate to severe heart
failure with a wide QRS complex (> 120 ms), current guidelines exclude many heart failure patients
with a narrow QRS. Detecting mechanical dyssynchrony on echocardiography has become a promising
tool in selecting patients with a narrow QRS who may respond to CRT. Several small single-center
studies identified patients with a narrow QRS (using echocardiography-based dyssynchrony criteria)
who responded favorably to CRT; however, the results of two recent pilot studies remain elusive. The
results of the RethinQ study do not provide necessary evidence for making clinical treatment decisions
in this population. The lack of definitive evidence is the strongest rationale for conducting an adequately
powered, long-term, end point-driven, randomized controlled trial to investigate whether CRT therapy
can improve morbidity and mortality outcomes in heart failure patients with a narrow QRS. Such a trial,
the EchoCRT trial, has recently been launched.
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Abstract 
While cardiac resynchronization therapy (CRT) is indicated in patients with moderate-
to-severe heart failure with a wide QRS complex (> 120 ms), current guidelines exclude a 
substantial number of patients with a narrow QRS. Detection of mechanical dyssynchrony on 
echocardiography has emerged as a promising tool to select patients with narrow QRS that 
may respond to CRT. While several small single center studies were able to identify patients 
with narrow QRS using echocardiography-based dyssynchrony criteria, who responded 
favorably to CRT, the results of two recent pilot studies remain elusive. Especially the initial 
experience from the RethinQ study does not provide the evidence necessary for making 
clinical treatment decisions in this population. This lack of definitive evidence is the strongest 
rationale for conducting an adequately powered, long-term, endpoint-driven, randomized 
controlled trial to investigate whether CRT therapy can improve morbidity and mortality 
outcomes in the large number of heart failure patients with narrow QRS, which has recently 
been launched.  
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Introduction 
Over 500.000 new patients each year are affected by the diagnosis of heart failure in 
the United States making it one of the biggest challenges to the Health Care System around 
the globe.1 Recently it has been shown in large clinical, randomized, controlled trials that 
cardiac resynchronization therapy (CRT) improves morbidity and mortality in patients with 
moderate-to-severe heart failure [New York Heart Association (NYHA) functional class III–
IV], left ventricular ejection fraction (LVEF) 35% or less, QRS > 120 ms on optimal medical 
therapy.2-4 However, a significant amount of patients meeting current guidelines are “non-
responders” based on clinical outcomes or echocardiographic remodeling.5 In contrast, the 
majority of heart failure patients has a narrow QRS complex (Figure 1),6 and is hence 
currently excluded to receive cardiac resynchronization.  
 
Definition of mechanical dyssynchrony 
Traditionally, cardiac dyssynchrony has been defined by prolongation of ventricular 
conduction measured by QRS-duration. Most of the currently available data on treatment 
success of CRT is therefore based on the selection of patients with a wide QRS complex (> 
120ms). QRS-duration reflects mainly interventricular dyssynchrony and displays the total 
ventricular electrical activation. Therefore a rapid RV-depolarisation may offset delays in left 
ventricular activation resulting in a normal QRS duration despite the presence of LV-
dyssynchrony.7 Several studies have demonstrated a weak predictive value of baseline QRS-
duration on response to CRT. 5 8 Hence, QRS-width clearly has its limitations as a single 
parameter for dyssynchrony; consequently, interventricular dyssynchrony might not be the 
ideal target of CRT.  
Several myocardial diseases go along with changes in cardiac structure and function, 
which result in regions of early and late LV-contraction leading to intraventricular mechanical 
dyssynchrony. Indeed, the latter has been identified as the main factor associated with 
impaired left-ventricular contractile function. As such, most of the current techniques for the 
assessment of cardiac dyssynchrony focus on left ventricular (intraventricular) dyssynchrony. 
However, various different approaches are emerging in its assessment. Pizalis et al. pioneered 
quantification of intraventricular dyssynchrony by measuring septal to posterior wall motion 
delay (SPWMD) in M-Mode images. A cut-off value of >130ms has been shown predictive 
for response to CRT in their initial study.9 Despite these results, SPMWD has several 
limitations and is only recommended as a supplemental parameter.10 The largest body of 
evidence comes from echocardiographic studies using different applications of tissue doppler 
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imaging (TDI)-based criteria. Using TDI to assess temporal delay between septal and lateral 
wall peak systolic velocity, Bax et al. demonstrated an opposing wall delay of >65ms to 
predict both clinical response to CRT as well as reverse remodelling.11 Yu et al. calculated the 
standard deviation (SD) of time to peak systolic velocity in 12 LV segments (‚Yu-Index’) and 
demonstrated a similar predictive value; this approach, however, is considerably more time 
consuming.12 Interestingly, Bleeker et al. found that 70% of patients with QRS-duration of 
>150ms showed severe mechanical dyssynchrony compared with only 27% of patients with a 
normal QRS duration. When QRS-duration was taken as a continuous variable, however, 
there was no relationship between QRS-duration and the extent of intraventricular 
dyssynchrony,13 which was further supported by a study by Yu et al.14 Considering that 27% 
of patients despite a narrow QRS complex exhibit significant intraventricular dyssynchrony 
by TDI, it is intriguing to speculate that these patients would also respond beneficially to 
CRT. This has been investigated in two smaller studies including 33 and 51 patients with 
QRS < 120ms. There was a similar improvement in symptoms and LV reverse remodeling 
compared to patients with a wide QRS complex and comparable intraventricular 
dyssynchrony (see below).15, 16   
Radial contraction or radial myocardial thickening, which is the main vector 
contributing to LV performance, can only insufficiently be analyzed by TDI due to inherent 
technical limitations (angle dependence). 2-D strain (speckle tracking) allows the assessment 
of radial LV-mechanics on the basis of routine gray-scale echocardiographic images. A cut-
off value of 130ms for the time difference in peak septal to posterior wall strain (in 
midventricular short-axis images) predicted a significant increase in LVEF with 89% 
sensitivity and 83% specificity. Interestingly a subset of patients not meeting the cut-off value 
of TDI (>65ms) but instead demonstrating significant radial dyssynchrony by speckle 
tracking had a favorable response to CRT.17, 18 In a recent study of 176 patients the two 
methods were combined; it was shown that patients who fulfilled both criteria had a high 
incidence of improvement after CRT, whereas patients with neither longitudinal nor radial 
dyssynchrony responded poorly, irrespective of QRS width.19 Delgado et al. recently 
compared the predictive value of different speckle-tracking parameters (radial, 
circumferential and longitudinal strain) and found radial strain to be the best predictor 
(sensitivity 83%, specificity 80%) for response to CRT using the same cut-off value of 
>130ms (Figure 2).20  
Just recently Lim et al. proposed a „longitudinal strain delay index“ by speckle 
tracking, defined as the sum of the difference between peak and end-systolic strain across 16 
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segments. Instead of measuring dyssynchrony,  this method quantifies the potential gain of 
contractility that can be expected. Furthermore, by analyzing all segments, myocardial scars 
are also taken into account. Application of the “longitudinal strain delay index” demonstrated 
a strong predictive value for the response to CRT.21   
Real-time 3D-Echocardiography is another new technique being used to quantify 
intraventricular dyssynchrony. It allows the comparison of synchrony between all segments 
using semiautomatic LV contour detection algorithms. A systolic dyssynchrony index (SDI) 
is derived from dispersion of time to minimum regional volume for all 16 segments. SDI 
increases with worsening LV-systolic function. Of note, 37% of patients with moderate to 
severe impairment in LV-function had significant dyssynchrony despite a normal QRS-
duration.22. Marsan et al. have shown a sensitivity of 88% and specificity of 85% to predict 
response to CRT using a SDI cut-off value of 6.4%.23. The main limitations of this technique 
lie in the  currently low spatial and temporal resolution with frame rates between 20 and 30/s.  
Besides echocardiography, which is primarily used in dyssynchrony analysis, several other 
imaging modalities have been applied. In particular, cardiac magnetic resonance imaging 
(CMR) has shown to provide highly quantitative and reproducible data.24, 25 Further methods 
are SPECT and CT, which will not further be discussed in this review.26, 27  
In summary, quantification of dyssynchrony is rather complex and there is currently 
no gold standard for the definition of mechanical dyssynchrony 10. As there are minor 
differences in regional function in normal hearts 28, pathophysiologically relevant 
dyssynchrony should not be diagnosed unless a certain threshold is identified. While in 
patients with a wide QRS complex interventricular and intraventricular dyssynchrony is 
frequently overt, it is more subtle in the case of narrow QRS. It is of pivotal importance to 
define criteria for dyssynchrony that are simple, reproducible and applicable to all patients 
with dyssynchrony.  
 
CRT in patients with a narrow QRS is effective in single center studies 
Several small single center studies have addressed the efficacy of CRT in heart failure 
patients with a narrow- as compared to those with a wide QRS complex based on 
echocardiographic criteria of dyssynchrony (table 1). In an early trial, 38 patients with a wide 
and 14 patients with a narrow QRS complex, all of whom had echocardiographic signs of 
inter- (interventricular delay >20 ms) and intraventricular asynchrony (posterolateral left 
ventricular wall activation delay > interval between QRS onset and beginning of transmitral 
filling), were compared. After 6 months of CRT, an improvement in NYHA functional class 
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and 6-minute walk distance as well as in LVEF, LVESD, LVEDD, and mitral regurgitation 
was observed to a similar degree in both groups.29   
In another study of 102 heart failure patients with functional NYHA class III or IV, 
TDI (standard deviation of the time to peak systolic velocity in12 LV segments > 32.6 ms) 
was used to depict subjects with mechanical LV asynchrony amongst the 51 patients with a 
narrow QRS. 3 months after CRT implantation, a reduction in LV end-systolic volume was 
observed in both the narrow and wide QRS patient group; along with this, an improvement of 
NYHA functional class, maximal exercise capacity, 6-min walk distance, LVEF, and mitral 
regurgitation was detected. In contrast, withholding CRT for 4 weeks resulted in loss of 
echocardiographic benefits. In both groups, LV reverse remodeling was determined to a 
similar extent by the degree of baseline mechanical asynchrony.16  
In a similar study, 33 consecutive patients with narrow QRS complex were 
prospectively compared to 33 consecutive patients with wide QRS complex. Inclusion criteria 
were NYHA functional class III or IV, LVEF ≤ 35%, and signs of LV dyssynchrony on TDI 
(maximum delay between peak systolic velocities among the 4 walls within the left ventricle 
≥ 65 ms). No significant relationship between baseline QRS duration and LV dyssynchrony 
was observed, and improvement in clinical symptoms (NYHA functional class, 6 minute walk 
distance, quality of life) or LV reverse remodeling (LV end-systolic volume reduction, 
increase in LVEF) after 6 months of CRT was similar in both groups.15 
 A meta-analysis of the three aforementioned trial confirmed an improvement by CRT 
in mean LVEF as well as in NYHA functional class in heart failure patients with narrow QRS 
complex.30 These small pilot studies hence demonstrate that patients selected on the basis of 
echocardiography-based asynchrony criteria can benefit from CRT independent of QRS 
duration. Interpretation is limited, however, due to the lack of hard endpoints, small sample 
size, and short duration of follow-up in these studies. 
 
Recent pilot multi-center studies assessing CRT in patients with a narrow QRS (table 2) 
In a recently published small pilot study (Cardiac Resynchronization Therapy in 
Patients with Heart Failure and Narrow QRS, RethinQ), 172 heart failure patients (126 with a 
narrow QRS (≤ 130msec) and 46 with a wide QRS complex (control group)) with a standard 
indication for an implantable cardioverter–defibrillator (ischemic or nonischemic 
cardiomyopathy and an ejection fraction ≤ 35%, NHYA functional class III), and evidence of 
mechanical dyssynchrony as measured on echocardiography were randomly assigned to CRT 
or to control (CRT off) for 6 months.31 The study failed to reach its primary end point defined 
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as an increase in peak oxygen consumption during cardiopulmonary exercise testing (46% vs. 
41%, respectively), while peak oxygen consumption increased in a pre-specified subgroup of 
patients with a QRS interval of 120 msec or more receiving CRT therapy. While an analysis 
of secondary endpoints in the RethinQ study is questionable due to the rejection of the 
primary hypothesis, the inconsistencies in the secondary endpoints showing no improvement 
in quality-of-life and 6-minute walking test, but a statistically significant improvement of 
NYHA class, reinforce the inadequate powering of the study to draw conclusions related to 
clinical endpoints. Furthermore, a 28% relative reduction in heart failure events (24 events in 
14 subjects [16.1%] in the CRT group, 41 events in 19 subjects [22.3%] in the control group) 
did not reach statistical significance, as there was no significant difference in mortality.  
Several other weaknesses are equally inherent to this study. First, the selection criteria 
chosen to investigate intra-ventricular asynchrony are likely not the best approach to 
determine patients likely to benefit from CRT. Based on recent data from other trials, well 
established parameters with greater accuracy to predict mechanical dyssynchrony, speckle-
tracking radial strain TDI in particular, are more appropriate to select candidates likely to 
respond to CRT as compared to the obsolete measurement of mechanical delay in septal-to-
posterior wall employed in RethinQ. Second, it is of note that large-scale and long-term 
clinical outcome trials, CARE-HF in particular, demonstrated that the clinical benefit of CRT 
becomes evident substantially later than after the six-month follow-up chosen in RethinQ, and 
increases over time, as it is expected from the beneficial impact of CRT on reverse left 
ventricular remodeling. Finally, and in contrast to previous and ongoing randomized clinical 
outcome trials with CRT, RethinQ was insufficiently powered to demonstrate clinical 
endpoints, and with only a six month follow-up period, too short to provide definite answers 
as to whether CRT reduces morbidity and mortality in heart failure subjects with narrow 
QRS. 
Similar to Rethinq, the multi-center ESTEEM-CRT trial (presented at Heart Rhythm 
Society, 2008) evaluated the effects of CRT in HF patients with a narrow QRS and signs of 
mechanical dyssynchrony. Inclusion criteria were EF ≤ 35%, QRS < 120msec, NYHA 
functional class III, and mechanical dyssynchrony as defined as the standard deviation of time 
to peak velocity of 12 segments (Ts-SD) > 28.7ms. After 6 months of CRT, no improvement 
in peak oxygen consumption, LVEF, or LV end-systolic volume was observed; in contrast, 
subjective measures such as life score and NYHA functional class improved significantly. 
Major limitations of ESTEEM-CRT included its non-randomized, single arm, unblinded 
design; hence, subjective measures such as functional class improvement are highly 
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susceptible to placebo effect. Furthermore, the same general concerns as for Rethinq apply. 
On the one hand, the employed TDI criteria may not have depicted patients suitable for CRT. 
More importantly, however, the single arm design, low patient number, and the short follow-
up period limit the validity of the study to assess the long-term effects of CRT on LV 
remodeling and, eventually, morbidity and mortality. Moreover, in contrast to single-center 
studies, interobserver variations in the assessment of dyssynchrony may be considerably 
higher across different centers in multi-center trials, which may have prevented uniform 
selection of appropriate patients. 
 The data from these two pilot multi-center trials hence provide a strong rational for an 
adequately powered, long-term, event-driven, randomized controlled trial to investigate 
morbidity and mortality in the large number of heart failure patients with narrow QRS. 
 
Assessing asynchrony in patients with wide QRS – the PROSPECT trial  
In the prospective, multi-center PROSPECT study (Predictors of Response to CRT), 498 
heart failure patients from 53 centers were enrolled who fulfilled standard CRT indications 
(NYHA functional class III or IV, LVEF ≤ 35%, QRS ≥ 130msec). After 6 months of CRT, 
the clinical composite score was improved in 69% of 426 patients and the LV end-systolic 
volume (≥15% reduction) in 56% of 286 patients. However, both sensitivity and specificity of 
the twelve echocardiographic parameters used in the assessment of dyssynchrony varied 
widely for the prediction of clinical outcomes (6-74% and 35-91%, respectively) or left 
ventricular end-systolic volume response (9-77% and 31-93%, respectively). 32 
In view of the modest sensitivity and specificity in this multicenter setting despite site 
training in acquisition methods and blinded core laboratory analysis, the authors concluded 
that no single echocardiographic measure of dyssynchrony may be recommended to improve 
patient selection for CRT beyond current guidelines. However, “response” to CRT is  not 
solely dependent on the echocardiographic modality used to diagnose dyssynchrony, but also 
on several other factors. Indeed, presence of a myocardial scar as well as myocardial 
viability,33, 34 position of LV lead placement,35 etiology of heart failure as well as suboptimal 
pacemaker programming (with or without echocardiographic guidance) have all been shown 
to significantly affect the response to CRT.7 Consequently, if these aspects are not addressed 
they may act as potent confounders, and even the most optimal echocardiographic measure of 
dyssynchrony may become useless.  
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Summary and Conclusion 
Currently available practice guidelines of patient selection for CRT are unsatisfactory; 
on the one hand, a substantial number of patients selected according to guidelines do not 
respond to CRT, while other potential responders (especially certain patients with a narrow 
QRS) are currently excluded from this potentially life-saving therapy. Hence, novel 
algorithms for patient selection are required, and detection of mechanical dyssynchrony on 
echocardiography has emerged as a promising tool in this regard. However, objective 
echocardiographic quantification of dyssynchrony is complex, and determining which criteria 
are optimal to identify patients most likely to respond to CRT as well as adoption of universal 
definitions to reduce inter- and intraobserver variation will be of pivotal importance. 
Furthermore, “response” to CRT is dependent on other factors such as lead positioning and 
optimal device programming, without which even the most optimal echocardiographic 
measure may become useless. While several small single center studies were able to identify 
patients with narrow QRS using echocardiography-based dyssynchrony criteria, who 
responded favorably to CRT, the results of two recent pilot studies remain elusive. Especially 
the initial experience from the RethinQ study does not provide the evidence necessary for 
making clinical treatment decisions in this population. This lack of definitive evidence is the 
strongest rationale for conducting an adequately powered, long-term, endpoint-driven, 
randomized controlled trial to investigate whether CRT therapy can improve morbidity and 
mortality outcomes in the large number of heart failure patients with narrow QRS.  
Such a trial is now underway (Echocardiography Guided Cardiac Resynchronization 
Therapy – EchoCRT; NCT00683696, www.clinicaltrials.gov). The EchoCRT trial evaluates 
the effects of CRT on morbidity and mortality in subjects with heart failure due to left 
ventricular systolic dysfunction with a narrow QRS width (<130 ms) and echocardiographic 
evidence of ventricular dyssynchrony. The primary efficacy objective of this trial is to 
demonstrate whether CRT (CRT=ON) will significantly reduce the combined endpoint of all-
cause mortality or first hospitalization for worsening heart failure (HF) - whichever comes 
first - in these subjects as compared to CRT=OFF therapy. 
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Legends to figures and tables:  
 
Figure 1:  
Proportion of patients with heart failure and left ventricular ejection fraction (LVEF) (35% in 
the EuroHeart Failure Survey. Of 5934 patients who had left ventricular function assessed, 
2107 (36%) had LVEF (35% and of these 888 (42%) had a QRS interval .120 ms. 
Reproduced with permission from Cleland et al.,36 data derived from Kahn et al.6 
 
Figure 2:  
(A) Normal heart. Peak radial strain of all segments occurs at the same time. (B) Patient with 
intraventricular radial dyssynchrony. Note the late peak of the posterior segment compared to 
the antero-septal segment.  
 
Table 1: 
Summary of single-center studies assessing the efficacy of CRT in heart failure patients with 
a narrow QRS complex 
CRT – Cardiac resynchronization therapy; LVEF — left ventricular ejection fraction; 
LVEDD — left ventricular; end-diastolic diameter; LVESV — left ventricular end-systolic 
volume; LVESD — left ventricular end-systolic diameter; NYHA — New York Heart 
Association heart failure class; TDI – Tissue doppler imaging 
 
Table 2: 
Summary of two small pilot multi-center studies assessing the efficacy of CRT in heart failure 
patients with a narrow QRS complex 
LVEF — left ventricular ejection fraction; LVEDD — left ventricular; end-diastolic diameter; 
LVESV — left ventricular end-systolic volume; LVESD — left ventricular end-systolic 
diameter; NYHA — New York Heart Association heart failure class; TDI – Tissue doppler 
imaging; VO2 max – Maximal oxygen consumption.  
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Table 1 
 
Study  Patient no. 
Echo criteria for 
dyssynchrony 
Outcomes  Results  Other 
38 (wide QRS)   NYHA functional class  improved Achilli et al., 
JACC 2006  14 (Narrow QRS)   6‐minute walk distance  improved 
 No difference between wide and narrow QRS 
groups 
       LVEF  improved   Study duration: 6 months 
       LVESD  improved   
     
 posterolateral left 
ventricular wall activation 
delay > interval between 
QRS onset and beginning 
of transmitral filling   LVEDD  improved   
       IVD  20 ms   Mitral regurgitation  improved   
51 (wide QRS)   LVESV  improved Yu et al.,  
JACC 2006  51 (Narrow QRS)   NYHA functional class  improved 
       6‐minute walk distance  improved 
 No difference between wide and narrow QRS 
groups, similar dyssynchrony at "baseline" 
provided 
     
 standard deviation of the 
time to peak systolic 
velocity in 12 LV segments 
> 32.6 ms (TDI)   Maximal exercise capacity  improved 
       LVEF  improved 
 Withholding CRT for 4 weeks resulted in loss of 
echocardiographic benefits 
         Mitral regurgitation  improved   Study duration: 3 months 
33 (wide QRS)   LVEF  improved Bleeker et al., 
JACC 2006  33 (Narrow QRS)   LVESV  improved 
 Similar outcomes between wide and narrow 
QRS groups 
       NYHA functional class  improved   Study duration: 6 months 
       6‐minute walk distance  improved   
     
 maximum delay between 
peak systolic velocities 
among the 4 walls within 
the left ventricle ≥ 65 ms 
(TDI) 
  
 Quality of life  improved   
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Table 2 
 
Study  Patient no.  Echo criteria for dyssynchrony  Outcomes  Results  Other 
126 (narrow QRS)   VO2 max  unchangedBeshai et al., 2007 
(RethinQ)  46 (wide QRS)   NYHA functional class  improved 
     
 mechanical delay in the septal‐to‐
lateral and anteroseptal‐to‐
posterior wall delay (TDI)   Quality of life  unchanged
 Failed primary endpoint, 
hence insufficient power 
for secondary endpoints 
       6‐minute walk distance  unchanged  Study duration: 6 months 
     
 mechanical delay in septal‐to‐
posterior wall (M‐mode echo)   Heart failure events  less (ns)   
68 (narrow QRS)   VO2 max  unchanged  Low patient number ESTEEM‐CRT (presented 
at Heart Rhythm 2008)      LVEF  unchanged  Unblinded, single arm 
     
 standard deviation of the time to 
peak systolic velocity in 12 LV 
segments > 28.7 ms (TDI)   LVESV  unchanged  No core laboratory 
          Quality of life  improved   Study duration: 6 months 
          NYHA functional class  improved    
 
